Cerenome (CNSY) closed at $0.71 on November 18, 2026, up 12.2% from the previous close, on volume of 327,972 shares (30-day average 1,511,546).
Data as of November 18, 2026.
Cerenome Earnings Call Highlights CNSide Growth and REYOBIQ Progress
TipRanks (Mon, 16-Nov 7:16 PM ET)
Cerenome Reports Preliminary REYOBIQ Safety and Efficacy Data
TipRanks (Mon, 16-Nov 8:22 AM ET)
Globe Newswire (Mon, 16-Nov 7:30 AM ET)
TipRanks (Sun, 15-Nov 1:00 AM ET)
Globe Newswire (Fri, 13-Nov 5:19 PM ET)
Plus Therapeutics GAAP EPS of -$1.14, revenue of $0.72M
Seeking Alpha News (Fri, 13-Nov 4:56 PM ET)
Brain Cancer Biotech Race Heats Up as NeOnc, Nuvation, Jazz and Cerenome Present New Data at SNO
Globe Newswire (Fri, 13-Nov 1:41 PM ET)
Globe Newswire (Thu, 12-Nov 7:30 AM ET)
Cerenome Appoints Director Ron Andrews as Chief Business Officer
Globe Newswire (Tue, 10-Nov 7:30 AM ET)
Cerenome Secures National In-Network Agreement with Aetna for CNSide
Globe Newswire (Wed, 4-Nov 7:30 AM ET)
Cerenome Inc is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.
Cerenome trades on the NASDAQ stock market under the symbol CNSY.
As of November 18, 2026, CNSY stock price climbed to $0.71 with 327,972 million shares trading.
CNSY has a beta of 17.88, meaning it tends to be more sensitive to market movements. CNSY has a correlation of 0.67 to the broad based SPY ETF.
CNSY has a market cap of $6.91 million. This is considered a Sub-Micro Cap stock.
Last quarter Cerenome reported $722,000 in Revenue and -$1.14 earnings per share. This beat revenue expectation by $22,000 and missed earnings estimates by -$.12.
The top ETF exchange traded funds that CNSY belongs to (by Net Assets): VTI, VXF, IWC.
CNSY support price is $.56 and resistance is $.70 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CNSY shares will trade within this expected range on the day.